^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peripheral T-cell Lymphoma
    Drug:Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    brentuximab vedotin (Adcetris) is accepted for use within NHSScotland

    Published date:
    12/04/2020
    Excerpt:
    brentuximab vedotin (Adcetris) is accepted for use within NHSScotland....in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
    Secondary therapy:
    CHP
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Peripheral T-cell Lymphoma: First-line therapy...Preferred regimen…Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and prednisone)...
    Secondary therapy:
    CHP